Full-Time

Senior Quality Assurance Specialist

Compliance

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$132k - $178.6k/yr

+ Annual bonus + Stock-based long-term incentives

West Greenwich, RI, USA

In Person

Bachelor's, Master's, PhD, Associate's

Category
QA & Testing (1)
Required Skills
Quality Assurance (QA)
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A high school diploma or GED and 12 years of regulatory compliance experience, or an associate’s degree and 10 years of regulatory compliance experience, or a bachelor’s degree and 6 years of regulatory compliance experience, or a master’s degree and 4 years of regulatory compliance experience, or a doctorate degree and 2 years of regulatory compliance experience.
  • Experience coordinating regulatory inspections, corporate audits, internal audits, and customer audits in a pharmaceutical manufacturing environment.
  • Experience with inspection readiness, quality systems, compliance, data analysis, project management, and Good Manufacturing Practice requirements.
  • Knowledge of European Union and United States current Good Manufacturing Practices.
  • Understanding of quality management systems and quality control processes related to bulk drug substance for commercial operations.
  • Ability to work autonomously, present data in an organized and logical manner, communicate effectively, navigate ambiguity, and apply a structured problem-solving approach.
  • Ability to coordinate cross-functional project teams and deliver work to expectations and on schedule.
Responsibilities
  • Coordinate site logistics for regulatory inspections, corporate audits, internal audits, and customer audits across both manufacturing facilities.
  • Serve as the primary site coordinator for inspection-readiness activities, including planning rooms and schedules, coordinating escorts and subject-matter-expert support, managing document retrieval processes and communications, and overseeing daily inspection activities.
  • Maintain a continuous inspection-ready state for a multi-product current Good Manufacturing Practice manufacturing operation.
  • Develop, maintain, and continuously improve site inspection-readiness programs, tools, trackers, playbooks, and governance processes.
  • Coordinate cross-functional readiness plans for Health Authority inspections and major audits, including mock inspections, war-room preparation, document review, and interview readiness.
  • Support inspection and audit strategy for new product introductions to ensure new processes, facilities, systems, documents, and personnel are inspection ready before implementation and filing-related activities.
  • Assign, track, escalate, and close inspection-related commitments, actions, and deliverables.
  • Facilitate alignment on inspection narratives, site presentations, supporting data packages, and response coordination.
  • Prepare and maintain inspection-readiness content, including site overviews, facility maps, product-flow summaries, subject-matter-expert rosters, document inventories, and inspection-support tools.
  • Coordinate document management and retrieval processes for controlled responses during inspections and audits.
  • Monitor readiness of quality systems and operational processes, including deviations, corrective and preventive actions, change control, complaints, training, validations, document management, and data-integrity controls.
  • Identify gaps, risks, and weak points affecting inspection outcomes and work with functional owners on timely remediation.
  • Support site self-assessments and gap assessments against current Good Manufacturing Practice requirements, internal standards, and regulatory inspection trends.
  • Maintain working relationships with internal stakeholders and external business partners to support audits and inspections.
  • Incorporate lessons learned from prior inspections, audits, commitments, and industry enforcement actions into site-readiness activities.
  • Track regulatory commitments and follow up to ensure inspection observations, actions, and commitments are completed and sustainable.
  • Provide compliance support during inspections through schedule management, room coordination, request tracking, communications, and facilitation of cross-functional issue resolution.
  • Support drafting, coordination, and review of inspection responses and related action plans.
  • Escalate significant quality, compliance, supply, and inspection-readiness risks to site quality and senior leadership.
  • Support continual-improvement initiatives that strengthen site quality culture, inspection-readiness capability, and execution discipline.
Desired Qualifications
  • Bachelor’s degree in Life Sciences or Engineering.
  • Experience leading or participating in key roles to prepare for, execute, or respond to Health Authority inspections.
  • Experience auditing or defending processes, procedures, and decisions during Health Authority inspections.
  • Seven or more years of related work experience in pharmaceutical manufacturing, process development, or quality assurance with progressively increasing responsibility.
  • Experience managing staff or leading cross-functional teams, projects, or programs.
  • Previous exposure to bulk drug substance manufacturing and quality assurance processes.
  • A track record of building or participating as a member of successful teams.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.